

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C07D 307/80, 307/79, 307/81 C07D 307/84, 405/06, 405/12 A61K 31/34	A1	(11) International Publication Number: WO 93/20057 (43) International Publication Date: 14 October 1993 (14.10.93)
(21) International Application Number: PCT/US93/02107 (22) International Filing Date: 10 March 1993 (10.03.93)		(74) Agent: MOON, Carolyn, D.; Merrell Dow Pharmaceuticals Inc., 2110 East Galbraith Road, P.O. Box 156300, Cincinnati, OH 45215-6300 (US).
(30) Priority data: 92400956.6 6 April 1992 (06.04.92) (34) Countries for which the regional or international application was filed: FR et al.	EP	(81) Designated States: AU, CA, FI, HU, JP, KR, NO, NZ, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(71) Applicant (for all designated States except US): MERRELL DOW PHARMACEUTICALS INC. [US/US]; 2110 East Galbraith Road, P.O. Box 156300, Cincinnati, OH 45215-6300 (US).		Published <i>With international search report.</i>
(72) Inventors; and (75) Inventors/Applicants (for US only) : GRISAR, J., Martin [US/FR]; Lottissement Wingersbach, 7, rue de Mulhouse, F-67160 Wissembourg (FR). PETTY, Margaret, A. [GB/FR]; 2, allée de la Robertsau, F-67000 Strasbourg (FR). BOLKENIUS, Frank [DE/DE]; Bierkellerstrasse 15B, D-7640 Kehl (DE).		

(54) Title: NOVEL DERIVATIVES OF 2,3-DIHYDRO-2,2,4,6,7-PENTAALKYL-5-BENZOFURANOLS

(57) Abstract

Derivatives of 2,3-dihydro-5-benzofuranol, intermediates thereof, and processes useful for their preparation. These compounds are free radical scavengers and are useful in the treatment of conditions capable of being treated by free radical scavengers, such as stroke, nervous system trauma and reperfusion damage.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam

NOVEL DERIVATIVES OF 2,3-DIHYDRO-2,2,4,6,7-PENTAALKYL-S-BENZOFURANOLS

This invention relates to certain derivatives of 2,3-dihydro-benzofuranol; to the intermediates and processes
5 useful for their preparation, to their ability to manifest the property of being free radical scavengers, and to their end-use application in the treatment of disease conditions capable of being ameliorated by free radical scavengers such as, for example, stroke, nervous system trauma or
10 reperfusion damage.

More specifically this invention relates to compounds of the formula

15




20

(1)

the stereoisomers and mixtures thereof, and their pharmaceutically acceptable salts thereof, wherein

25

- 2 -


- R₂ is C₁₋₄ alkyl or both R₂ moieties, when taken together with the carbon atom to which they are attached, form a C₅₋₆ cyclic hydrocarbyl moiety;
- R₄ is C₁₋₆ alkyl;
- 5 R₅ is H or -C(O)R with R being H, or C₁₋₉ alkyl;
- R₆ is C₁₋₆ alkyl;
- R₇ is H or C₁₋₆ alkyl;
- X is COOR₈, CH₂OH, halomethyl, C(O)A or -CH₂A;
- A is -NR₇R₉, -N[⊕]R₆R₆R₆-Q[⊖], pyrrolidino, piperidino
- 10 morpholino, or -NN-R₁₀;
- R₈ is H, C₁₋₆ alkyl, or -(CH₂)_m-A, with m being 2,3 or 4;
- R₉ is H, C₁₋₄ alkyl, -(CH₂)_n-(R₁₁)_p, n is
- 15 1, 2, 3 or 4, p is 1,2 or 3;
- R₁₀ is H, C₁₋₈ alkyl, C₁₋₆ alkenyl, C₄₋₆ cycloalkyl, cyclohexylmethyl, hydroxyalkyl (C₂₋₆), dihydroxyalkyl (C₃₋₆), C₂₋₉ acyloxyalkyl (C₂₋₆), C₁₋₄ alkoxyalkyl (C₁₋₆),
- 20 -(CH₂)₂₋₆-O-(CH₂)₂₋₄ OH, -(CH₂)_t-R₁₂, with t
- being 0, 1, or 2, or pyrimidinyl;
- R₁₁ is H, C₁₋₄ alkoxy, C₁₋₄ alkyl or halogeno;
- R₁₂ is ortho C₁₋₄ alkoxy, ortho C₁₋₄ alkyl or p-halo;
- 25 Q is a halogen[⊖] or -SO₃R₁ with R₁ being H, C₁₋₆ alkyl, aryl or aralkyl.

As used herein the term "alkyl" includes the straight and branched chain saturated aliphatic hydrocarbyl moieties having the indicated number of carbon atoms, preferably methyl or ethyl, but including others such as propyl, isopropyl, n-butyl and the like. The term -C(O)R includes moieties wherein R is H or a C₁₋₉ alkyl moiety, embracing, for example, formyl, methylcarbonyl, ethylcarbonyl,

35

- 3 -

propylcarbonyl and the like. The $-\text{NR}_7\text{R}_9$ moieties include the amino and mono and di-substituted amines with R_7 ,

and R_9 being as defined. The $-(\text{CH}_2)_m$ 

moiety includes benzyl, phenylethyl, phenylpropyl or phenylbutyl moieties; the phenyl moieties of which may bear 1,2 or 3 substituents represented by R_{11} selected from the group consisting of C_{1-4} alkoxy (preferably methoxy) C_{1-4} alkyl (preferably methyl) or halogen (preferably chloro but including bromo and iodo). Similarly, mono and di-hydroxy substituted alkyl moieties are those moieties wherein the alkyl moiety can bear one or two OH groups (other than two hydroxy groups on one carbon atom), preferably moieties bearing a hydroxy group on a terminal carbon atom. C_{2-9} acyloxy alkylene (C_{2-6}) are those compounds wherein the acyloxy moiety has 2 to 9 carbon atoms and the alkylene moiety has 2 to 6 carbon atoms such as exemplified by $-\text{CH}_2\text{CH}_2-\text{OC}(\text{O})\text{CH}_3$. The $-\text{C}_{2-6}$ alkylene-O— $(\text{CH}_2)_{2-4}$ OH moieties have respectively a divalent 1-6 carbon atom moiety attached to an oxygen (O). The oxygen is also attached to a 1-4 carbon moiety terminating in a hydroxy moiety. One example is $-\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2\text{CH}_2\text{OH}$. Piperidino is illustrated by

$\text{CH}_2-(\text{CH}_2)_2\overset{|}{\text{N}}-\text{CH}_2\text{CH}_2$, morpholino by $\text{O}-(\text{CH}_2)_2\overset{|}{\text{NH}}-\text{CH}_2-\text{CH}_2$

and pyrrolidino $\text{CH}_2\text{CH}_2\overset{|}{\text{N}}-\text{CH}_2\text{CH}_2$. It is preferred that

both R_2 alkyl moieties be the same (e.g. 2,2-dimethyl or 2,2-diethyl) but both need not be the same for any one compound. Similarly in those instances wherein A represents a tertiary amine both of R_7 and R_9 are preferably the same, preferably both being methyl or ethyl, and when R_9 is other than H or alkyl, benzyl is preferred. The moiety $-\text{N}^{\oplus}\text{R}_6\text{R}_6\text{R}_6$.

- 4 -

Q^E represents a quaternary ammonium moiety wherein Q includes all halides with chloro and bromo being preferred, and aryl includes phenyl or its alkylated derivatives with toluene as the preferred species and aralkyl includes 5 benzyl or phenethyl and their alkylated derivatives.

The pharmaceutically acceptable salts include those acid addition salts derived by reaction with such acids as hydrochloric, hydrobromic, sulfuric, nitric or phosphoric 10 acids and such organic carboxylic acids as acetic, propionic, glycolic, maleic, tartaric, citric, salicylic, 2-acetoxybenzoic acids or organic sulfonic acids such as methanesulfonic 4-toluenesulfonic as naphthalensulfonic acids. Of course other acids well known to the pharmaceutical art may also be utilized. 15


The compounds of the present invention may exist in stereoisomeric forms, and the present invention is meant to include all stereoisomeric forms. The term "stereoisomer" 20 is a general term for all isomers of individual molecules that differ only in the orientation of their atoms in space. It includes mirror image isomers (enantiomers), geometric (cis/trans) isomers, and isomers of compounds with more than one chiral center that are not mirror images 25 of one another (diastereoisomers). It is recognized that certain stereoisomeric forms of the present invention may have properties which are superior to other stereoisomeric forms or mixtures thereof. These properties may be a better therapeutic response, better bioavailability, lower 30 toxicity or any other desirable property. Standard methods of separation may be used to isolate the preferred stereoisomer.

In general, the compounds of formula I may be prepared 35 by standard chemical processes and techniques analogously

- 5 -

known in the art with the overall processes depicted in the following Reaction Schemes A, B and C.

REACTION SCHEME A



wherein $\text{R}_2, \text{R}_4, \text{R}_6$ and R_7 are as previously defined and B is
 $-\text{C}(\text{R}_2)=\text{C}(\text{R}_2)_2$, Pg is a protecting group, and including
 O

the oxygen to which it is attached forms an ester or an ether moiety, and is preferably para-nitrobenzoyl. Detailed aspects of the reaction steps (a) to (g) are summarized as follows: step (a) $\text{C}_6\text{H}_5\text{CH}_3$, reflux 1 hour; step (b) AlCl_3 , 145° , 1.5 hour; step (c) 1N NaOH , 50% MeOH , reflux 1 hour; step (d) $4-\text{O}_2\text{N-C}_6\text{H}_4\text{COCl}$, Pyridine, room temperature,

- 6 -

16 hours; step (e) thallium(III)(NO₃)₃.3H₂O, (CH₃O)₃CH,
MeOH, room temperature, 4 days; step (f) tetrahydrofuran, 2N
NaOH, reflux 1 hour; step (g) 1 N NaOH 50% MeOH, reflux
24 hours.

5


Using the Fries rearrangement of substituted acrylic acid diesters (3) of hydroquinones (2) gives 6-hydroxy-3,4-dihydro-1,2H-benzopyran-4-ones (4) as taught by N.V. Dudykina et al., *Khim. Gererotsikl. Soedin*, 1969, 434-439

10 (Chem. Abstr., 1970, 72, 31545X). This reaction is carried out using a Lewis acid, preferably anhydrous aluminum chloride, at elevated temperatures, preferably at 120-150°C, usually without a solvent. 3,3-Dimethyl, diethyl, tetramethylene and pentamethylene acrylic acid esters are 15 preferably employed for this reaction and the hydroquinone is a 2,3-dialkyl or a 2,3,6-trialkyl substituted hydroquinone, the alkyl preferably being methyl. Only a few examples of the ring-contraction reaction of 3,4-dihydro-1(2H)-benzopyran-4-ones to 2,3-dihydro-1-benzofuran-3-20 carboxaldehydes or -carboxylic acid esters (6) have been reported previously. Oxidative rearrangement of enolizable ketones (5) with thallium(III)nitrate in trimethylortho-formate as taught by A. Mc Killip and E.C. Taylor (for a review see *Endavor*, 1976, 35, 88) and extended to ring 25 contraction of benzopyran to benzofuran derivatives (S. Antus et al., *Chem. Ber.*, 1979, 112, 3879-3885 and G. Ciattini et al., *J. Heterocycl. Chem.*, 1982, 19, 395-400). However, due to the simultaneous formation of other reaction products, the yields of rearranged product are 30 generally poor. In applying this reaction to 6-hydroxy-substituted derivatives of 3,4-dihydro-1(2H)-benzopyran-4-ones (5) it is found that the choice of the protective group of these phenols greatly influences the yield of rearranged product. Thus, using the 6-acetoxy derivatives 35 as starting materials, a 30-60% of rearranged product (with

- 7 -

considerable difficulties in reproducibility) is obtained, the 6-benzyloxy derivative gave less than 10% of rearranged product. The use of 6-(*p*-nitrobenzoyl)oxy derivative 5 gave consistently good yields of 80-90% of 6 that is readily isolated without the need of chromatographic separation procedures. Thus, although thallium reagents have to be handled with great care because of their toxicity, the simplicity of the procedure and the high yields render this reaction suitable for large scale preparation of 2,3-dihydro-1-benzofuran derivatives that are otherwise not readily accessible.

REACTION SCHEME B



wherein R, R₂, R₄, R₆, R₇ and A are as previously defined.

- 8 -

The acids (7) can readily be reduced to the alcohols (8). Borane-dimethylsulfide complex is the preferred reagent for this reaction using tetrahydrofuran as solvent but other hydride reagents, such as lithium aluminum hydride can be used as well as other non-reactive solvents.

5 Due to the steric hindrance which the 2,2-dialkyl substitution imparts, unusually long reaction times, preferably 16 to 48 hours, and elevated temperatures (reflux) are required. Conversion of the alcohols (8) to

10 bromides (9) is best accomplished using bromotriphenylphosphonium bromide, obtained from triphenylphosphine and bromine in dichloromethane. The use of triphenylphosphine and tetrabromomethane in dimethylformamide gives less favorable results, even with extended reaction time.


15 Conversion of the bromide to the iodide can be accomplished by refluxing it in acetonitrile with one equivalent of sodium iodide. Conversion of the bromides or iodides (9) to amine-substituted products (10) can be accomplished by procedures well known to the art, but again employing

20 extended reaction time and elevated reaction temperatures to overcome steric hindrance. Thus, using dimethylformamide at 60-80°C or acetonitrile at reflux temperature the reaction of bromide (9) with an amine such as 1-methylpiperazine for 2 to 5 days will lead to acceptable yields

25 of products (10). Protection of the phenolic hydroxy group by acylation to (11) is necessary in some instances, or desired in others, to obtain acylated products (12). The latter can also be obtained by acylation of (10) and the resulting products (11) may then be converted to compounds

30 (12).

- 9 -

REACTION SCHEME C

The acid (7), after protection of the phenolic hydroxy group to (13), can be converted to acid chlorides (14) using triphosgene (bistrichloromethyl carbonate) or diphosgene (trichloromethyl chloroformate) in the presence of triethylamine in an inert solvent, such as dichloromethane. Reaction of (14) with alcohols HOR₈, R₈ being as

35

- 10 -

defined above, gives esters (15), which can be hydrolyzed selectively to (16) due to the steric hindrance of the 3-carboxylic ester group. Reaction of (14) with secondary or primary amines gives amides (17), which can be
5 hydrolyzed to (18).

Further, as there is an asymmetric carbon atom at the 3-position, the compounds may occur as either the R- or the S-enantiomers, or mixtures thereof. The preparation of the
10 individual enantiomeric form may be effected by resolving the acids of Formula (13) by standard and conventional means such as, for example, via the use of diastereomeric salts with optically active amines, or alternatively, by resolving the alcohols (8) as esters with optically active
15 acids, e.g. L-2,4-MeClC₆H₃CHMeCOOH (Me representing methyl).

Having generically described the methods for the preparation of the compounds of this invention, the following examples describe the details of the processes
20 and techniques involved.

25

30

35

- 11 -

EXAMPLE 1

2,3-DIHYDRO-5-HYDROXY-2,2,4,6,7-PENTAMETHYL-1-BENZOFURAN-3-CARBOXYLIC ACID

5

STEP A:

3,4-Dihydro-6-hydroxy-2,2,5,7,8-pentamethyl-2H-1-benzopyran-4-one

- 10 To 100 g of 3,3-dimethylacrylic acid is added 73 ml of thionyl chloride and the mixture is stirred for 2 hours at room temperature and for 1.5 hours at 110°C. Distillation at 40 mm gives 107.0 g (90%) of 3,3-dimethylacryloyl chloride, b.p. 66-68°C. It is added to a solution of
- 15 68.68 g of trimethylhydroquinone in 500 ml of toluene and the mixture is slowly heated to reflux and stirred at that temperature for 1 hour. After cooling and addition of some ethyl ether the solution is washed with saturated sodium bicarbonate solution and is dried over sodium sulfate.
- 20 Filtration and evaporation of solvent gives an oil that is crystallized from 700 ml of hexane to give 133.16 g (93%) of the bis-(3,3-dimethylacryloyl) ester of trimethylhydroquinone.
- The ester is pulverized and mixed with 61.74 g (10% excess)
- 25 of anhydrous aluminium chloride by means of a mechanical stirrer and heated to 135-145°C for 1.5 hours. The resulting melt is allowed to cool, dissolved in 200 ml of dichloromethane and 200 ml of 2N hydrochloric acid is added dropwise. The dichloromethane phase is separated, washed
- 30 with sodium bicarbonate and a sodium chloride solution and dried over sodium sulfate. Filtration and evaporation of solvent gives an oil that is treated with 300 ml of methanol and 300 ml of 2N sodium hydroxide solution at reflux temperature for 1 hour. The mixture is cooled,
- 35 acidified with 400 ml of 2N HCl and extracted twice with

- 12 -

ethyl acetate. The extract is washed with water and sodium bicarbonate, dried over sodium sulfate, filtered and concentrated to about 300 ml. The product, 3,4-dihydro-6-hydroxy-2,2,5,7,8-pentamethyl-2H-1-benzopyran-4-one, 5 crystallizes and is recrystallized from ethyl acetate to give 53.84 g. A second crop of 13.29 g raises the yield to 68%.

STEP B:

10 2,3-dihydro-5-(4-nitrobenzoyl)oxy-2,2,4,6,7-pentamethyl-1-benzofuran-3-carboxylic acid, methyl ester

The p-nitrobenzoyl ester of this material (see Step A) is prepared by portionwise addition of 38.98 g of p-nitro-15 benzoyl chloride to an ice-cooled solution of 46.86 g of 3,4-dihydro-6-hydroxy-2,2,5,7,8-pentamethyl-2H-1-benzopyran-4-one in 250 ml of pyridine and stirring at room temperature overnight. Water is added and the solid is collected and washed with water and a little methanol.

20 Recrystallization from chloroform/methanol gives 74.62 g (97%).

A heterogenous mixture of 30.20 g (0.079 mol) of 3,4-dihydro-6-(4-nitrobenzoyl)oxy-2,2,5,7,8-pentamethyl-2H-1-benzopyran-4-one, 36.86 g (0.083 m) of thallium (III) 25 nitrate trihydrate, 200 ml of trimethylorthoformate, and 200 ml of methanol is stirred at room temperature for 4 days. The resulting solid is collected and washed with methanol. The residue is slurried in 100 ml of chloroform and filtered; this process is repeated three times. The 30 combined filtrates are heated to boiling and the chloroform is gradually replaced by an equal volume of methanol until crystallization occurs to give 27.44 g (84%) of 2,3-di-hydro-5-(4-nitrobenzoyl)oxy-2,2,4,6,7-pentamethyl-1-benzofuran-3-carboxylic acid, methyl ester, m.p. 215-216°C.

- 13 -

Elemental analysis, IR, UV, and ¹H-NMR spectra confirm the structure.

This procedure was scaled up to 402 g, and 380.9 g (87.8%) of product was obtained.

5

STEP C:

Methyl-2,3-Dihydro-5-hydroxy-2,2,4,6,7-pentamethyl-1-benzofuran-3-carboxylate

- 10 Treatment of a boiling solution of 20.67 g (0.05 mol) of this material (see Step B) in 200 ml of tetrahydrofuran with 50 ml of 2N sodium hydroxide for 1 hour is followed by evaporation of solvent (20 minutes), addition of water, and extraction with dichloromethane (three times). The extract
15 is washed with water and a sodium chloride solution, dried over sodium sulfate, filtered and evaporated. The resulting solid is recrystallized from ethyl acetate/heptane to give 10.96 g (81%) of methyl 2,3-dihydro-5-hydroxy-2,2,4,6,7-pentamethyl-1-benzofuran-3-carboxylate, m.p. 145-146°C.
20 Elemental analysis, IR, UV, and ¹H-NMR spectra confirm the structure.

STEP D:

2,3-Dihydro-5-hydroxy-2,2,4,6,7-pentamethyl-1-benzofuran-3-carboxylic acid

- Refluxing 22.36 g of the above material (see Step C) in 100 ml of methanol and 100 ml of 2N sodium hydroxide for 24 hours is followed by acidification with 120 ml of 2N
30 hydrochloric acid, evaporation of methanol, and extraction with ethyl acetate (twice). The extract is washed with water and acidic product is extracted into a sodium bicarbonate solution, which upon acidification is re-extracted with ethyl acetate. The extract is dried over
35 sodium sulfate, filtered and evaporated. The resulting

- 14 -

solid is recrystallized from ethyl acetate/heptane to give 16.40 g (77%) of 2,3-dihydro-5-hydroxy-2,2,4,6,7-pentamethyl-1-benzofuran-3-carboxylic acid, m.p. 161-164°C. Elemental analysis, IR, UV, and ¹H-NMR spectra confirm the
5 structure.

EXAMPLE 2

10 2,3-DIHYDRO-5-HYDROXY-2,2,4,6,7-PENTAMETHYL-1-BENZOFURAN-3-METHANOL

To a stirred solution of 58.82 g (0.235 mol) of 2,3-dihydro-5-hydroxy-2,2,4,6,7-pentamethyl-1-benzofuran-3-carboxylic acid (see Example 1) in 500 ml of dry tetrahydrofuran is added dropwise over 30 minutes 50 ml of 10M borane-methyl sulfide and the resulting mixture is stirred at reflux temperature for 7 hours. After cooling, 120 ml of methanol is added carefully and the resulting solution is evaporated to dryness. The residue is taken up in ethyl acetate and the solution is washed with 2N hydrochloric acid, water, a sodium bicarbonate solution, and brine, and is dried over anhydrous sodium sulfate. Filtration and evaporation of solvent gives an oil that crystallizes from ethyl acetate/heptane to give 37.85 g of the title compound, m.p. 89-90°C.
Elemental analysis, IR, UV, and ¹H-NMR spectra confirm the structure. A second crop of 12.60 g is obtained, raising the yield to 91%.

30

35

- 15 -

EXAMPLE 3

3-BROMOMETHYL-2,3-DIHYDRO-2,2,4,6,7-PENTAMETHYL-1-BENZO-
FURAN-5-OL AND O-ACETATE

5

To an ice-cooled solution of 41.89 g (0.1595 mol = 10% excess) of triphenylphosphine in 120 ml of 4A molecular sieve-dried dichloromethane is added dropwise a solution of 24.33 g (0.152 mol = 5% excess) of bromine in 40 ml of 10 dichloromethane. The resulting mixture is stirred at 0°C for 1 hour (any remaining coloration by bromine is removed by additional addition of triphenylphosphine). To the bromotriphenylphosphonium bromide reagent thus prepared is added 34.26 g (0.145 mol) of 2,3-dihydro-5-hydroxy- 15 2,2,4,6,7-pentamethyl-1-benzofuran-3-methanol and the resulting solution is stirred and allowed to warm up to room temperature for 18 hours. The solution is concentrated to a small volume and is chromatographed on silica gel using dichloromethane/hexane (1:2) as eluent. Fractions 20 containing the product (as indicated by thin layer chromatography) are combined and evaporated to dryness to give 46.05 g. Crystallization from ethyl acetate/heptane gives a solid, m.p. 79-80°C. Elemental analysis, IR, UV, and ¹H-NMR spectra confirm the structure.

25

To a solution of 12.58 g of this material in 150 ml of pyridine is added 70 ml of acetic anhydride. After stirring at room temperature overnight, ice water is added and the resulting precipitate is collected, taken up in ethyl 30 acetate, washed with 2N hydrochloric acid, water, a sodium bicarbonate solution, and brine, and dried over anhydrous sodium sulfate. Filtration and evaporation of solvent gives

35

- 16 -

13.30 g of the O-acetate of the title compound that crystallizes from ethyl acetate/heptane, m.p. 122-123°C. Elemental analysis, IR, UV, and ¹H-NMR spectra confirm the structure.

5

EXAMPLE 4

2,3-DIHYDRO-2,2,4,6,7-PENTAMETHYL-3-DIMETHYLAMINOMETHYL-1-

10 BENZOFURAN-5-OL, HYDROCHLORIDE

Into 8 ml of dry dimethylformamide is bubbled dimethylamine gas until a volume of 10 ml is obtained. This solution is added to a solution of 4.98 g of 3-bromomethyl-

15 2,3-dihydro-2,2,4,6,7-pentamethyl-1-benzofuran-5-ol (see Example 3) in 20 ml of dimethylformamide, and the stoppered mixture is stirred at room temperature for 7 days. Water

and a sodium bicarbonate solution is added and the mixture is extracted with ethyl ether. The extract is washed twice

20 with water and the basic product is separated by washing with 2N hydrochloric acid and water. These washes are basified by addition of solid sodium bicarbonate and

reextracted into ethyl acetate. After drying over anhydrous sodium sulfate, filtration and evaporation, 2.80 g of an

25 oil is obtained. This is dissolved in isopropanol and isopranolic hydrogen chloride is added to pH below 3. The resulting crystals are recrystallized from isopropanol to give 1.90 g of the title compound, m.p. 265-267°C (decomposition). Elemental analysis, IR, UV, and ¹H-NMR

30 spectra confirm the structure.

- 17 -

EXAMPLE 5

2,3-DIHYDRO-5-HYDROXY-N,N,N-2,2,4,6,7-OCTAMETHYL-1-BENZO-
FURAN-3-METHANAMINIUM 4-METHYLBENZENSULFONATE

5

A mixture of 4.28 g of 2,3-dihydro-2,2,4,6,7-penta-methyl-3-dimethylaminomethyl-1-benzofuran-5-ol (see Example 4) and 3.3 g (10% excess) of methyl 4-methylbenzenesulfonate in 60 ml of acetonitrile is refluxed for 10 18 hours. The solvent is evaporated and the residue is slurried in ethyl acetate. The resulting semi-solid is recrystallized twice from acetonitrile to give 3.7 g of the title compound, m.p. 244-245°C. Elemental analysis, IR, UV, and ¹H-NMR spectra confirm the structure.

15

EXAMPLE 6

2,3-DIHYDRO-2,2,4,6,7-PENTAMETHYL-3-(1-METHYLETHYLAMINO)-
20 METHYL-1-BENZOFURAN-5-OL HYDROCHLORIDE

Following the procedure described in Example 4 but substituting dimethylamine by isopropylamine (10 equivalents) the title compound is obtained, m.p. 274-276°C 25 (decomposition). Elemental analysis, IR, UV, and ¹H-NMR spectra confirm the structure.

30

35

- 18 -

EXAMPLE 7

2,3-DIHYDRO-2,2,4,6,7-PENTAMETHYL-3-(1-PIPERIDINO)METHYL-1-BENZOFURAN-5-OL

5

Following the procedure described in Example 4 but substituting dimethylamine by piperidine (2 equivalents) the title compound is obtained, m.p. 273-275°C (decomposition). Elemental analysis, IR, UV, and ¹H-NMR spectra confirm the structure.

10

EXAMPLE 8

15 2,3-DIHYDRO-2,2,4,6,7-PENTAMETHYL-3-(4-METHYLPiperAZINO)-METHYL-1-BENZOFURAN-5-OL DIHYDROCHLORIDE

A solution of 2.99 g of the compound described in Example 3 and 1.50 g of sodium iodide in 40 ml of acetonitrile is stirred at reflux temperature for 5 hours. After cooling, the mixture is filtered to remove sodium bromide that precipitates (0.81 g). To the filtrate is added 1.05 g of 1-methylpiperazine and the mixture is refluxed for 3 days. Sodium bicarbonate (1 equivalent) is added, the solvent is evaporated and the residue is taken up in ethyl acetate. The basic product is separated by washing with 2N hydrochloric acid and water, the washes are basified by addition of sodium bicarbonate, and the product is reextracted into ethyl acetate. After drying over anhydrous sodium sulfate, filtration and evaporation, 1.90 g of an oil is obtained. This oil is dissolved in isopropanol, and isopropanolic hydrogen chloride is added

- 19 -

to pH below 3. The resulting crystals are recrystallized from isopropanol to give the title compound, m.p. 268-269°C (decomposition). Elemental analysis, IR, UV, and ¹H-NMR spectra confirm the structure.

5

EXAMPLE 9

5-ACETOXY-2,3-DIHYDRO-2,2,4,6,7-PENTAMETHYL-3-(4-METHYL-10 PIPERAZINO)METHYL-1-BENZOFURAN DIACID MALEATE

To a solution of 1.90 g of the compound described in the preceding example (as free base) in 20 ml of pyridine is added 10 ml of acetic anhydride and the solution is 15 stirred overnight. After addition of ice water and solid sodium bicarbonate (until no more carbon dioxide evolves) the product is extracted twice with ethyl acetate and the extract is washed with water and brine, and dried over anhydrous sodium sulfate. Filtration and evaporation of 20 solvent gives an oil that is dried under high vacuum to remove traces of pyridine. The residue is dissolved in isopropanol and is added to a solution of 1.75 g of maleic acid in isopropanol. The resulting crystals are recrystallized from isopropanol to give the title compound, m.p. 25 172-173°C (decomposition). Elemental analysis, IR, UV, and ¹H-NMR spectra confirm the structure.

30

35

- 20 -

EXAMPLE 10

2,3-DIHYDRO-3-[4-(2-HYDROXYETHYL)PIPERAZINO]METHYL-
2,2,4,6,7-PENTAMETHYL-1-BENZOFURAN-5-OL DIACID MALEATE

5 A solution of 5.59 g of the compound described in Example 3 and 2.62 g of 1-(2-hydroxyethyl)piperazine in 40 ml of dry dimethylformamide is stirred at room temperature for 4 days and at 50°C for 2 days. Water and
10 1 equivalent of sodium bicarbonate are added and the product is extracted into ethyl acetate. The basic product is separated by washing with 2N hydrochloric acid and water, the washes are made alkaline by addition of sodium bicarbonate and the product is reextracted into ethyl
15 acetate (3.44 g). Addition to a solution of 4.64 g of maleic acid in isopropanol and recrystallization from isopropanol gives 4.7 g of the title compound, m.p. 113-119°C. Elemental analysis, IR, UV, and ¹H-NMR spectra confirm the structure.

20

EXAMPLE 11

5-ACETOXY-3-[4-(2-ACETOXYETHYL)PIPERAZINO]METHYL-2,3-
DIHYDRO-2,2,4,6,7-PENTAMETHYL-1-BENZOFURAN DIACID MALEATE

Treating the compound described in the preceding example as free base with acetic anhydride in pyridine, as described in Example 9 gives the title compound, m.p. 160-
30 162°C (decomposition). Elemental analysis, IR, UV, and ¹H-NMR spectra confirm the structure.

35

- 21 -

EXAMPLE 12

2,3-DIHYDRO-3-[4-[2-(2-HYDROXYETHOXY)ETHYL]PIPERAZINO]-
METHYL-2,2,4,6,7-PENTAMETHYL-1-BENZOFURAN-5-OL DIACID

5 MALEATE

A mixture of 2.99 g of the compound described in Example 3, 1.83 g (5% excess) of 1-[2-(2-hydroxyethoxy)-ethyl]piperazine, 1.50 g (1 equivalent) of sodium iodide and 10 0.84 g (1 equivalent) of sodium bicarbonate in 40 ml of acetonitrile is refluxed for 3 days. The solvent is evaporated and the residue is taken up in ethyl acetate and washed with water. The basic product is separated by washing with 2N hydrochloric acid and water, the washes are 15 made alkaline by addition of sodium bicarbonate and reextracted with ethyl acetate. The extract is dried over anhydrous sodium sulfate, filtered and evaporated to give 2.85 g (73%) of product, which is then dissolved in isopropanol and is added to a solution of 2.32 g of maleic 20 acid in isopropanol. The resulting crystals are recrystallized from isopropanol to give 3.34 g of the title compound, m.p. 124-126°C (decomposition). Elemental analysis, IR, UV, and ¹H-NMR spectra confirm the structure.

25

EXAMPLE 13

2,3-DIHYDRO-2,2,4,6,7-PENTAMETHYL-3-[4-(2-PYRIMIDINYL)-
PIPERAZINO]METHYL-1-BENZOFURAN-5-OL ACID MALEATE

30

A solution of 2.61 g (0.011 mol) of 1-(2-pyrimidyl)-piperazine dihydrochloride in 20 ml of water is made alkaline with a saturated potassium carbonate solution and the free base is extracted with toluene. The extract is 35 evaporated and to the residue is added 2.99 g (0.01 mol) of

- 22 -

the compound described in Example 3, 1.50 g (0.01 mol) of sodium iodide, 0.84 g (0.01 mol) of sodium bicarbonate and 50 ml of acetonitrile. The mixture is stirred at reflux temperature for 3 days. The solvent is evaporated and the residue is taken up in ethyl acetate and washed with water. The basic product is separated by washing with 2N hydrochloric acid and water, the washes are made basic by addition of sodium bicarbonate and reextracted with ethyl acetate. The extract is dried over sodium sulfate, filtered and evaporated. To the residue is added a solution of 2.32 g (0.02 mol) of maleic acid in isopropanol and the resulting crystals are recrystallized from isopropanol to give 3.5 g of the title compound, m.p. 161-162°C (decomposition). Elemental analysis, IR, UV, and ¹H-NMR spectra confirm the structure.

EXAMPLE 14

20 2,3-DIHYDRO-2,2,4,6,7-PENTAMETHYL-3-[4-(PHENYLMETHYL)-PIPERAZINO]METHYL-1-BENZOFURAN-5-OL DIACID MALEATE

Following the procedure described in Example 10, but substituting 1-(2-hydroxyethyl)piperazine by a molar equivalent of 1-benzylpiperazine results in the title compound, m.p. 134-137°C. Elemental analysis, IR, UV, and ¹H-NMR spectra confirm the structure.

30

35

- 23 -

EXAMPLE 15

2,3-DIHYDRO-2,2,4,6,7-PENTAMETHYL-3-[[2-(3,4-DIMETHOXY-PHENYL)ETHYL]METHYLAMINO]METHYL-1-BENZOFURAN-5-OL ACID

5 MALEATE

A solution of 2.99 g of the compound described in Example 3 and 1.50 g of sodium iodide in 40 ml of acetonitrile is refluxed overnight with stirring. The 10 precipitated sodium bromide is removed by filtration and 1.95 g of N-methylbromoveratrylamine and 0.84 g of sodium bicarbonate is added to the filtrate. The resulting mixture is stirred at reflux temperature for 5 days. The solvent is evaporated and the residue is taken up in ethyl acetate and 15 washed with water. The basic product is separated by washing with 2N hydrochloric acid and water, the washes are basified by addition of sodium bicarbonate and the product is reextracted into ethyl acetate. After drying over anhydrous sodium sulfate, filtration and evaporation, an 20 oil is obtained, which is then dissolved in isopropanol and is added to a solution of 1.16 g of maleic acid in isopropanol. The resulting solid is recrystallized from isopropanol to give the title compound.

25

30

35

- 24 -

EXAMPLE 16

3-AMINOMETHYL-2,3-DIHYDRO-2,2,4,6,7-PENTAMETHYL-1-BENZO-
FURAN-5-OL HYDROCHLORIDE

5

A mixture of 4.75 g of 5-acetoxy-3-bromomethyl-2,3-dihydro-2,2,4,6,7-pentamethyl-1-benzofuran (see Example 3) and 2.58 g (1 equivalent) of potassium phthalimide in 50 ml of dry dimethylformamide is stirred at 60°C for 48 hours.

10 Water is added and the product is extracted twice with ethyl ether. The extract is washed with water and brine, and is dried over anhydrous sodium sulfate. After filtration, evaporation of the solvent leaves a residue that is crystallized from ethyl acetate/heptane. The first 15 crop contains free phthalimide, but subsequent crops yield 2,3-dihydro-2,2,4,6,7-pentamethyl-3-phthalimidomethyl-1-benzofuran-5-ol acetate.

A solution of this material in 50 ml of methanol and 50 ml of 2N sodium hydroxide is refluxed for 6 hours. After 20 addition of 70 ml of 2N hydrochloric acid, methanol is removed by evaporation and the remaining aqueous phase is washed twice with ethyl acetate to remove non-basic product. The aqueous phase is made alkaline by addition of sodium bicarbonate and is extracted twice with ethyl 25 acetate. The extract is dried over anhydrous sodium sulfate, filtered and evaporated. The residue is dissolved in ethyl ether and enough of ethereal hydrogen chloride is added to obtain a pH below 3. The hydrochloride salt is recrystallized from isopropanol/ethyl ether to obtain the 30 title compound.

EXAMPLE 173R and 3S-Enantiomers of 5-ACETOXY-2,3-DIHYDRO-2,2,4,6,7-5-PENTAMETHYL-1-BENZOFURAN-3-CARBOXYLIC ACID

To a solution of 25.03 g (0.1 M) of 2,3-dihydro-5-hydroxy-2,2,4,6,7-pentamethyl-1-benzofuran-3-carboxylic acid (described in Example 1) in 200 ml of pyridine is
10 added 100 ml of acetic anhydride and the mixture is stirred at room temperature for 24 hours. Water and ice is added and the mixture is stirred at about 30°C for 30 minutes. More ice and 450 ml of 6 N hydrochloric acid is added and the resulting solid is collected, washed with water, and
15 taken up in ethyl acetate. The solution is washed with 2 N hydrochloric acid and water and is dried over anhydrous sodium sulfate. The residue obtained after filtration and evaporation of solvent is recrystallized from ethyl acetate to give 23.6 g (81%) of the title compound as racemate,
20 m.p. 187-8°C. Elemental analysis, UV, and ¹H-NMR spectra confirm the structure.

A solution of 15.27 g (0.0523 M) of this material and 6.65 g (0.0523 M) of S-(-)- α -methylbenzylamine in 100 ml of isopropanol, 2 ml of water and 300 ml of ethyl acetate is
25 azeotroped to a volume of about 100 ml. The crystalline material obtained on cooling is recrystallized twice from the same solvent system to give 6.02 g (56%) of the diastereomeric salt, $\alpha_{D}^{25} = -13.81^{\circ}$ (0.99% in CH₃OH), ee = 99.5% by HPLC.

30 The combined filtrates are suspended in water, 50 ml of 2 N hydrochloric acid is added and the acidic product is extracted twice with ethyl acetate. The extract is washed with 2 N hydrochloric acid and sodium chloride solution, dried over anhydrous sodium sulfate, filtered and
35 evaporated to give 11.34 g of an oil. To this is added

- 26 -

4.70 g (0.0388 m) of R-(+)- α -methylbenzylamine and crystallization results using the same solvent system. Two recrystallizations gave 7.90 g (73%) of the other diastereoisomeric salt, $\alpha_{D}^{25} = -14.21^\circ$ (0.99% in CH₃OH), ee 5 = 99.1%. X-Ray crystallography shows this enantiomer to have the S-configuration.

EXAMPLE 18

10

3R-(+)- and 3S-(-)-ENANTIOMERS OF 2,3-DIHYDRO-2,2,4,6,7-PENTAMETHYL-3-(4-METHYLPIPERAZINO)-METHYL-1-BENZOFURAN-5-OL DIHYDROCHLORIDE HYDRATE

15 The two diastereometric salts described in the preceding example are each converted to the free acid, reduced to the alcohols with borane-methyl sulfide, as described in Example 2, converted to the bromide, as described in Example 3, and allowed to react with 1-methylpiperazine as 20 described in Example 8.

The enantiomer obtained from the R-acid is, by definition, the S-enantiomer of the title compound, $\alpha_{D}^{25} = -20.66^\circ$ (1.67% in water, pH = 1.3), ee = 99.7% by HPLC. Elemental analysis, UV and ¹H-NMR spectra confirm the structure.

25 The enantiomer obtained from the S-acid is, by definition, the R-enantiomer of the title compound $\alpha_{D}^{25} = +20.68^\circ$ (1.18% in water, pH = 1.40), ee = 99.7% by HPLC. Elemental analysis, UV and ¹H-NMR spectra confirm the structure.

30

35

- 27 -

EXAMPLE 19

5-ACETOXY-2,3-DIHYDRO-2,2,4,6,7-PENTAMETHYL-1-BENZOFURAN-5-CARBOXYL CHLORIDE

5

To a solution of 9.59 g (0.047 M) of trichloromethyl chloroformate in 80 ml of dry dichloromethane under nitrogen is added dropwise over 3 hours a solution of 13.75 g (0.047 M) of 5-acetoxy-2,3-dihydro-2,2,4,6,7-

10 pentamethyl-1-benzofuran-5-carboxylic acid (described in Example 17, racemate) and 4.77 g (0.047 M) of triethylamine in 100 ml of dichloromethane. The escaping gas is trapped over potassium hydroxide. The mixture is stirred at room temperature overnight and at reflux temperature for 1 hour.

15 The residue obtained after evaporation of solvent at 30°C is suspended in toluene and the resulting precipitate of triethylamine hydrochloride is removed by filtration. The filtrate is evaporated and the residue is crystallized from hexane to give 10.93 g (75%) of the title compound, m.p.

20 171-173.5°C. Elemental analysis, UV and ¹H-NMR spectra confirm the structure.

The identical product is obtained using bistrichloromethyl carbonate (triphosgene) instead of diphosgene in the above procedure.

25

EXAMPLE 20

2,3-DIHYDRO-5-HYDROXY-2,2,4,6,7-PENTAMETHYL-1-BENZOFURAN-3-CARBOXYLIC ACID ESTER with 1-(2-HYDROXYETHYL)-4-METHYL-

30 PIPERAZINE DIACID MALEATE

To a solution of 3.48 g (0.0112 M) of the acid chloride described in the preceding Example in toluene is added

35 1.62 g (0.0112 M) of 4-methylpiperazin-1-ethanol, prepared

- 28 -

from 4-methylpiperazine and ethylene oxide, and the mixture is refluxed overnight. After cooling the solution is washed with sodium bicarbonate solution, dried over anhydrous sodium sulfate, filtered and evaporated. The residue is
5 refluxed in 50 ml of tetrahydrofuran and 25 ml of 2 N sodium hydroxide for 45 minutes. After acidifying with 60 ml of 2 N hydrochloric acid, the solution is washed with ethyl ether, sodium bicarbonate is added, and the product is extracted into ethyl acetate. The extract is dried over
10 anhydrous sodium sulfate, filtered and evaporated and 2.60 g of maleic acid is added to the residue in acetonitrile. Recrystallization from the same solvent gives 2.0 g of the title compound, m.p. 150-154°C. Elemental analysis, UV and ¹H-NMR spectra confirm the structure.

15

EXAMPLE 21

2,3-DIHYDRO-2,2,4,6,7-PENTAMETHYL-3-(4-METHYLPIPERAZINE-1-CARBOXY)-1-BENZOFURAN-5-OL ACID MALEATE

A solution of 4.22 g of the acid chloride described in Example 19 and 1.36 g of 1-methylpiperazine in 150 ml of toluene is refluxed for 4 hours. After cooling, the basic
25 product is extracted into 2 N hydrochloric acid, the solution is neutralized with sodium bicarbonate and the product is reextracted into ethyl acetate. The extract is dried over anhydrous sodium sulfate, evaporated, and the residue is crystallized from ethyl acetate/heptane to give
30 4.35 g (77%) of the O-acetate of the title compound, m.p. 171-173.5°C. This material is refluxed in 25 ml of methanol and 25 ml of 2 N sodium hydroxide for 45 minutes, methanol is evaporated and the residue is acidified with 2 N hydrochloric acid. The resulting solution is washed with ethyl acetate, made basic with sodium bicarbonate and extracted
35

- 29 -

with ethyl acetate. The extract is dried over anhydrous sodium sulfate, filtered and evaporated. One equivalent of maleic acid is added and the salt is crystallized and recrystallized from isopropanol/water to give the title 5 compound, m.p. 227°C (decomposition). Elemental analysis, UV and ¹H-NMR spectra confirm the structure.

EXAMPLE 22

10

2,3-DIHYDRO-2,2,4,6,7-PENTAMETHYL-3-[4-(2-HYDROXYETHYL)-PIPERAZINE-1-CARBOXY]-1-BENZOFURAN-5-OL ACID MALEATE

To 2.73 g (0.021 M) of 1-(2-hydroxyethyl)piperazine in 15 50 ml of toluene is added 2.28 g (0.021 M) of trimethylsilyl chloride. The solution is stirred for 3 hours at room temperature, washed with sodium bicarbonate solution, dried over anhydrous sodium sulfate and filtered. 6.22 g (0.02 M) of the acid chloride described in Example 19 is added and 20 refluxed for 5 hours. After cooling some ethyl acetate is added and the solution is washed with sodium bicarbonate solution, water, 2 N hydrochloric acid and water. The acidic washes are neutralized with sodium bicarbonate and extracted with ethyl acetate. The extract is dried over anhydrous sodium sulfate, filtered and evaporated to give 25 5.20 g of an oil. To remove the silyl group 20 ml of 1 M tetrabutylammonium fluoride in tetrahydrofuran is added, the solution is allowed to stand at room temperature overnight, the solvent is evaporated and the residue is taken up in ethyl acetate. The solution is washed with sodium 30 bicarbonate solution, dried over anhydrous sodium sulfate, filtered and evaporated. To hydrolyze the O-acetate the residue is refluxed in 25 ml of methanol and 25 ml of 2 N sodium hydroxide for 1 hour, methanol is evaporated and the 35 residue is acidified with 2 N hydrochloric acid. The

- 30 -

resulting solution is washed with ethyl acetate, made basic with sodium bicarbonate and extracted with ethyl acetate. The extract is dried over anhydrous sodium sulfate, filtered and evaporated. One equivalent of maleic acid is added 5 and the salt is crystallized and recrystallized from isopropanol/water/ethyl acetate to give 2.85 g (30%) of the title compound, m.p. 184-5°C (decomposition). Elemental analysis, UV and ¹H-NMR spectra confirm the structure.

10

EXAMPLE 23

The compounds of the present invention can be tested for efficacy in stroke and nervous system trauma by the method described in *J. Neurosurgery* 62:882-887 (1985). Male CD-1 mice weighing 18-22 g are subjected to head injury produced by a 50 g weight dropped 32 cm. 15 The neurological status is evaluated one hour later. Treatment of the mice with the compounds of interest can be pre-trauma or post-trauma. Improvement of neurological 20 status of the treated mice shows efficacy. For testing efficacy in reperfusion injury, the compounds of the present invention can be tested according to the method described in *Stroke* 20: 1037-1043 (1989). Male Sprague-Dawley rats weighing 250-300 g are subjected to 25 occlusion of middle cerebral artery followed by reperfusion. Reduction of infarct size shows efficacy in the treated rats.

30

35

The compounds of this invention are free radical scavengers. Free radical reactions have been implicated in the pathology of more than 50 human diseases. Radicals and other reactive oxygen species are formed constantly in the 5 human body both by deliberate synthesis (e.g. by activated phagocytes) and by chemical side-reactions. They are removed by enzymic and non-enzymic antioxidant defence systems. Oxidative stress, occurring when antioxidant defences are inadequate, can damage lipids, proteins, 10 carbohydrates and DNA. A few clinical conditions are caused by oxidative stress, but more often the stress results from the disease and can make a significant contribution to the disease pathology. For a more detailed review see B. Halliwell in *Drugs*, 1991, 42, 569-605.

15

There is a growing body of information that suggests a pathophysiologic role of oxygen free-radical-mediated lipid peroxidation following central nervous system trauma or stroke, either ischemic or haemorrhagic. A reduction in 20 cerebral tissue concentration of endogenous antioxidants has been observed, as well as an increase in lipid peroxidation products. Inhibitors of brain lipid peroxidation counteract and reduce cerebral tissue damage, as well as to prolong life of traumatized animals. These 25 findings have been reviewed by E.D. Hall and J.M. Braughler in *Free Radical Biology and Medicine*, 1989, 6, 303-313 and elsewhere. M. Miyamoto et al., (*J. Pharmacol. Exp. Ther.*, 1989, 250, 1132) report that neurotoxicity due to excessive glutamic acid release is similarly reduced by anti- 30 oxidants. They suggest the use of agents that inhibit brain lipid peroxidation for treatment of neurodegenerative diseases such as Huntington's and Alzheimer's disease in which excessive glutamic acid release has been observed. M.R. Hori et al., (*Chem. Pharm. Bull.* 1991, 39, 367) report on

35

- 32 -

anti-amnesic activity of brain lipid peroxidation inhibitors in rats.

The role of oxygen free radicals in Parkinson's disease
5 has been reviewed recently (*Free Radical Biol. Med.*, 1991, 10,
161-169) and a free radical scavenger has been tested
clinically with some success (*Fundam. Clin. Pharmacol.*, 1988,
2, 1-12).

Ischemia followed by reperfusion causes formation of
10 oxygen-derived free radicals and increased lipid peroxidation and results in tissue injury. Administration of free radical scavengers to animals subjected to ischemia/reperfusion reduces these effects in heart, lung, kidney, pancreas, brain and other tissues.

15 The compounds of the present invention are also useful in treating the process of inflammation which is known to involve the release of superoxide radicals from phagocytic cells which cause some of the symptoms of rheumatoid
20 arthritis and other inflammatory diseases such as ulcerative colitis. Inhalation injury of the lungs is typically caused by heat and chemical irritation, and chemical injury is the leading lethal cause of smoke inhalation injury. Smoke inhalation leads to lung injury
25 due to an increase in pulmonary microvasculature and pulmonary edema. This process is accompanied by increased lipid peroxidation in lung tissue. An inhibitor of lipid peroxidation was shown to reduce these symptoms in animals subjected to hot sawdust smoke by Z. Min et al., (*J. Med. Cell. PLA*, 1990, 5, 176-180). They suggest the use of anti-
30 oxidants in treatment of smoke inhalation-lung injury, adult respiratory distress syndrome and emphysema.

Reactive oxygen species also play a role in the
35 formation of foam cells in atherosclerotic plaques

(reviewed by D. Steinberg et al., *New Engl. J. Med.*, 1989, 320, 915-924) and the free radical scavenger probucol has a marked antiatherosclerotic effect in hyperlipidemic rabbits (Carew et al., *Proc. Nat. Acad. Sci. USA*, 1987, 84, 7725-7729).

5 Degenerative retinal damage and diabetogenic retinopathy have also been listed as target for treatment with free radical scavengers (cf. J.W. Baynes, *Diabetes*, 1991, 40, 405-412; S.P. Wolff et al., *Free Rad. Biol. Med.*, 1991, 10, 339-352).

10

The compounds may also be useful in the treatment of cancers, and degenerative diseases related to aging, stroke, and head trauma, since oxygen-derived free radicals have been identified among causative factors. For reviews, 15 see B. Halliwell and C. Gutteridge, *Biochem. J.*, 1984, 219, 1-14; TINS 1985, 22-6. Antioxidants have also been shown to be useful in the treatment of cataracts, *Free Rad. Biol. Med.*, 12:251-261 (1992).

20

In vitro and *in vivo* activity for the compounds of this invention may be determined by the use of standard assays which demonstrate the free radical scavenging property, affinity for cardiac tissue and cardioprotective properties, as well as by comparison with agents known to 25 be effective for these purposes.

30

Exemplary of the assay useful for determining the free-radical scavenging property of the compounds of this invention is by the *in vitro* inhibition of lipid peroxidation in rat brain homogenates.

35

The free radical scavenging properties of the compounds may readily be evaluated in an assay wherein superoxide radicals are generated by 4 mU of xanthine oxidase in the presence of 0.1 mM xanthine and detected by reduction of

- 34 -

40 μ M nitro blue tetrazolium (NBT) to the diformazan dye in a spectrophotometric assay as described by C. Beauchamp and I. Fridovick, (*Analyt. Biochem.* 1971, 44, 276-287). 30 U of superoxide dismutase inhibited this reduction by 90% which 5 is due to superoxide radicals. In the presence of a superoxide scavenger (test compound) there is a competition for the superoxide radical and thus a reduction in the color formation of NBT demonstrates the superoxide radical scavenging property of the test compound.

10

Inhibiting the process of lipid peroxidation may be assayed using tissue homogenates for measuring the antioxidant activity of biological fluids by the methodology of J. Stocks et al., (*Clin. Sci. Mol. Med.*, 1974, 15 47, 215-222), wherein a brain tissue homogenate of treated adult Sprague Dawley rats is utilized.

Samples of total volume 1 ml of diluted brain homogenate and with the scavenger at an appropriate dilution 20 are incubated. Non-incubated samples are taken as background. Controls are run without scavenger and a sample containing only buffer is taken as blank. After incubation at 37°C for 30 minutes, 200 μ l of 35% perchloric acid is added, the samples centrifuged and 800 μ l of the supernatants mixed with 200 μ l of 1% thiobarbituric acid. The 25 pink condensation product of thiobarbituric acid reactive material is developed at 100°C in a boiling water bath for 15 minutes, and absorbance read at 532 nm.

30 For *ex vivo* inhibition of tissue including heart or brain tissue, lipid peroxidation in mice may be utilized to demonstrate the ability of the compounds to penetrate and act as free radical scavengers in these tissues. This assay involves pretreatment of male CD1 mice by subcutaneous 35 administration of the test compound. One hour later the

tissues are excised, homogenized 1+9 (w/v) in 20 mM potassium phosphate buffer at pH 7.3 (0.14 M KCl) and incubated at 1/100 concentration in 1 ml of buffer at 37°C for 30-120 minutes. At the end of the incubation 200 µl of 5 35% perchloric acid is added and proteins removed by centrifugation. To 800 ml of the supernatant are added 200 µl of 1% TBA and the samples are treated to 100°C for 15 minutes. The TBA-adduct is extracted into 2 times 1 ml of n-butanol. The fluorescence is measured at an excitation 10 wavelength of 515 nm and an emission wavelength of 553 nm against a standard prepared from malondialdehyde dimethyl-acetal.

Stimulated human leukocytes release radicals and other 15 oxygen metabolites, which, during inflammation, act as microbicidal agents. At the same time, they release proteolytic enzymes, such as elastase, which are also microbicidal but potentially threaten the connective tissue of the host. An endogenous α_1 -proteinase inhibitor (α_1 Pi) 20 normally protects the host tissue from proteolytic digestion. α_1 Pi is however, inactivated by the leukocyte-derived oxidants. Antagonism of the of α_1 Pi is an indication of the disclosed radical scavengers. The concentration needed to protect 50% of the elastase inhibitory capacity 25 of α_1 Pi (PC_{50}) depends on the amount of stimulated leukocytes present.

Method: The procedure described by Skosey and Chow was followed (see J.L. Skosey and D.C. Chow in *Handbook of 30 Methods for Oxygen Radical Research* (Greenwald, R.A., ed.) 1985, pp.413-416, CRC Press, Boca Raton). In short, human α_1 Pi was incubated with zymosan-stimulated human peripheral-blood leukocytes in the absence or presence of the scavengers. The amount of α_1 Pi protected from oxidative inactivation was 35 determined by its residual elastase inhibitory capacity.

- 36 -

The relevance to inflammation matter has been reviewed by Weiss (see S.J. Weiss, *N. England J. Med.*, 1989, 320, 365-376). Lung emphysema is associated with a genetic defect in α_1 Pi; the disease is further enhanced by oxidants inhaled during cigarette smoking, which leads to oxidative inactivation of α_1 Pi in the lung tissue (see J. Travis and G.S. Salvesen, *Annu. Rev. Biochem.*, 1983, 52, 655-709). Oxidized α_1 Pi has also been isolated from rheumatoid synovial fluid (see P.S. Wong and J. Travis, *Biochem. Biophys. Roc. Commun.*, 1980, 06, 1440-1454). The degradation of hyaluronic acid, a macromolecule accounting for the viscosity of synovial fluid, is triggered by superoxyl radicals released from human leukocytes *in vitro* (see R.A. Greenwald and S.A. Moak, *Inflammation*, 1986, 10, 15-30). Furthermore, nonsteroidal anti-inflammatory drugs were shown to inhibit the release of superoxyl radicals from leukocytes (see H. Strom and I. Ahnfelt-Ronne, *Agents and Actions*, 1989, 26, 235-237 and M. Roch-Arveiller, V. Revelant, D. Pharm Huy, L. Maman, J. Fontagne, J.R.J. Sorenson and J.P. Giroud, *Agents and Actions*, 1990, 31, 65-71), and 5-aminosalicylic acid may exert its therapeutic activity in inflammatory bowel disease by a radical scavenger mechanism (see I. Ahnfelt-Ronne, O.H. Nielsen, A. Christensen, E. Langholz, V. Binder and P. Riis, *Gastroenterology*, 1990, 98, 1162-1169). Therefore, it is believed that the compounds of this invention may be useful in the mentioned pathologic situations and that inflammatory bowel disease may be a special target. An immune stimulatory effect of antioxidants has also been reported in that they enhanced lymphocyte activity (R. Anderson and P.T. Lukey, *Ann. N.Y. Acad. Sci.*, 1987, 498, 229-247) *in vitro* in the presence of triggered leukocytes, and *ex vivo* after pretreatment of human volunteers.

Thus, using standard and well known methodology, as well as by comparison with known compounds found useful, it is to be found that the compounds are free radical scavengers useful in the prevention and treatment of such disease states related to neurotoxicity due to excessive glutamic acid release, to Huntington's disease, Alzheimer's disease and other cognitive dysfunctions, (e.g. memory, learning and attention deficits), amnesia, and Parkinson's disease, as well as the treatment and prevention of tissue damage in heart, lung, kidney, pancreas and brain tissues induced by ischemia/reperfusion, and to allay acute blood loss due to haemorrhagic shock.

The compounds of the present invention are of particular interest in treating patients with stroke, nervous system trauma, and reperfusion damage. As used herein, these terms have the following meanings:

- a) stroke means cerebrovascular disease which includes cerebral insufficiency due to transient disturbances of blood flow, infarction, and arteriovenous malformation which causes symptoms of mass lesion, infarction, or hemorrhage.
- b) nervous system trauma means injury to the head or spine. For example, injury can occur from skull or spine penetration or from rapid brain acceleration or deceleration which injures tissue at the point of impact, at its opposite pole or within the frontal or temporal lobes. Injury may consist of nerve tissue, blood vessels and/or meninges damage resulting in neural disruption, ischemia and/or edema.; and

c) reperfusion damage means the damage that occurs in any blood-deprived tissue, anywhere in the body, upon reintroduction of the blood supply. For example, reperfusion of an ischemic area of the
5 myocardium or the cerebrum.

The compounds of this invention can be utilized both prophylactically and therapeutically. The amount of active ingredient for therapeutic administration can vary over a
10 wide range and is dependent upon such factors as the species of patient to be treated, its age, health, sex, weight, nature and the severity of the condition being treated. The term "patient" refers to a warm-blooded animal such as, for example, rats, mice, dogs, cats, guinea pigs,
15 primates and humans. Generally, a therapeutically effective amount of the active ingredient to be administered will range from about 0.1 mg/kg to 30 mg/kg of body weight per day. For prophylactic administration, corresponding lower doses can be utilized. Preferably, the compounds of the
20 present invention will be administered to the patient in combination with a pharmaceutically acceptable carrier which is any substance which aids in the administration of the compound without substantially affecting its therapeutic properties.
25

Most preferably, the compounds are administered intravenously particularly under crisis situations wherein it is essential that the therapeutic agent be gotten to its site of action as quickly as possible, such as in those
30 emergency conditions caused by coronary infarction, stroke and surgical interventions, conditions which can cause severe reperfusion damage.

The compounds of this invention also can be orally administered, preferably using more active ingredient per
35

day than when parenterally administered, preferably taking divided doses 3 to 4 times per day. Preferably, enteral administration in post "crisis" situations, particularly after release from hospitalized conditions. The compounds 5 can be used in standard dosage unit forms such as tablets, capsules, dragees, lozenges, elixirs, emulsions, suspensions, and in cases wherein topical application is preferred by suppository or sub-lingual administration. Tablets and capsules containing from 100 to 400 mg of 10 active ingredient are preferred modes of enteral administration. Of course, in the treatment of inflammation the preferred method of administration is by depot injection directly to the situs of the inflammation area with follow-up enteral means of administration.

15

In preparing solid dose forms such as tablets, the active ingredient is generally blended with conventional pharmaceutical carriers or excipients such as gelatin, various starches, lactose, calcium phosphate or powdered 20 sugar. The term pharmaceutical carrier as used herein also includes lubricants employed to improve the flow of tablet granulations and which prevent adhesion of tablet material to the surfaces of tablet dies and punches. Suitable lubricants include, for example, talc stearic acid, calcium 25 stearate, magnesium stearate and zinc stearate. Also included within the definition of a pharmaceutical carrier as used herein, are disintegrating agents added to assist the breakup and dissolution of tablets following administration, as well as coloring and/or flavoring agents to 30 enhance the aesthetic qualities of the tablets and make them more acceptable to the patient.

Suitable liquid excipients for the preparation of liquid dosage unit forms include water and alcohols such as 35 ethanol, benzyl alcohol and the polyethylene glycols,

- 40 -

either with or without the addition of a surfactant. In general, the preferred liquid excipients, particularly for injectable preparations, include water, physiological and saline solutions, dextrose and glycol solutions such as an aqueous propylene glycol or polyethylene glycol solutions. In order to minimize or eliminate irritation at the site of injection, such compositions may contain a non-ionic surfactant having a hydrophile-lipophile balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulations ranges from about 5 to 15% by weight. The surfactant can be a single component having the above-identified HLB, or a mixture of two or more components having the desired HLB. Illustrative of surfactants useful in parenteral formulations are the class of polyoxyethylene sorbitan fatty acid esters as, for example, sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol. In certain topical and parenteral preparations, various oils can be utilized as carriers or excipients. Illustrative of such oils are mineral oils, glyceride oils such as lard oil, cod liver oil, peanut oil, sesame oil, corn oil and soybean oil. For insoluble compounds, suspending agents may be added as well as agents to control the viscosity, as for example, magnesium aluminum silicate or carboxymethyl-cellulose. In addition to these excipients, buffers, preservatives and emulsifying agents may also be added. Typical enema preparation of the retention type enema utilizes small volumes, generally much less than about 150 mL for an adult, typically volumes of only a few milliliters are preferred. Excipients and solvents for use in retention enemas should, of course, be selected so as to avoid colonic irritation and should also be selected so as to minimize absorption of the various agents.

The compounds of this invention can also be administered topically. This can be accomplished by simply preparing a solution of the compound to be administered, preferably using a solvent known to promote transdermal absorption such as ethanol or dimethyl sulfoxide (DMSO) with or without other excipients. Preferably topical administration will be accomplished using a patch either of the reservoir and porous membrane type or of a solid matrix variety.

10


Some suitable transdermal devices are described in U.S. Pat. Nos. 3,742,951, 3,797,494, 3,996,934, and 4,031,894. These devices generally contain a backing member which defines one of its face surfaces, an active agent permeable adhesive layer defining the other face surface and at least one reservoir containing the active agent interposed between the face surfaces. Alternatively, the active agent may be contained in a plurality of microcapsules distributed throughout the permeable adhesive layer. In either case, the active agent is delivered continuously from the reservoir or microcapsules through a membrane into the active agent permeable adhesive, which is in contact with the skin or mucosa of the recipient. If the active agent is absorbed through the skin, a controlled and predetermined flow of the active agent is administered to the recipient. In the case of microcapsules, the encapsulating agent may also function as the membrane.

In another device for transdermally administering the compounds in accordance with the present invention, the pharmaceutically active compound is contained in a matrix from which it is delivered in the desired gradual, constant and controlled rate. The matrix is permeable to the release of the compound through diffusion or microporous flow. The release is rate controlling. Such a system, which requires

- 42 -

no membrane is described in U.S. Pat. No. 3,921,636. At least two types of release are possible in these systems. Release by diffusion occurs when the matrix is non-porous. The pharmaceutically effective compound dissolves in and 5 diffuses through the matrix itself. Release by microporous flow occurs when the pharmaceutically effective compound is transported through a liquid phase in the pores of the matrix.


10 The compounds of the present invention may be incorporated into an aerosol preparation by means commonly known to those skilled in the art. The aerosol preparation may be prepared for use as a topical aerosol or may be prepared for inhalation. The aerosol preparation may be in 15 the form of a solution or suspension and may contain other ingredients such as solvents, propellants and/or dispersing agents. Typical examples of aerosol preparations are shown in *Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Company, Easton Pennsylvania, pp. 1694-1712 (1990)* incorporated 20 herein by reference.

As it is true for most classes of compounds suitable for use as therapeutic agents certain subclasses and certain specific compounds are more preferred than others. 25 In this instance it is preferred that the R₂, R₄, R₆ and R₇ moieties be methyl. Preferably R₅ is H or an acyl moiety including formyl and acetyl. X is preferably CH₂A. A is preferably -N; R₁₀ is preferably C₁₋₆ alkyl, 30 more preferably C₁₋₃ alkyl and most preferably methyl. Other preferred forms of R₁₀ are acyloxyalkylene, especially -CH₂-O-C(O)CH₃, hydroxyalkyl (C₂₋₆) especially (CH₂)₂-OH, and pyrimidinyl.

WHAT IS CLAIMED IS:

1. A compound of the formula

5



10

(1)

the stereoisomers and mixtures thereof, and their pharmaceutically acceptable salts thereof, wherein
 15 R_2 is C_{1-4} alkyl or both R_2 moieties, when taken together with the carbon atom to which they are attached, form a C_{5-6} cyclic hydrocarbyl moiety;


R_4 is C_{1-6} alkyl;

R_5 is H or $-C(O)R$ with R being H, or C_{1-9} alkyl;

20 R_6 is C_{1-6} alkyl;

R_7 is H or C_{1-6} alkyl;

X is $COOR_8$, CH_2OH , halomethyl, $C(O)A$ or $-CH_2A$;

A is $-NR_7R_9$, $-N^{\oplus}R_6R_6R_6-Q^{\ominus}$, pyrrolidino, piperidino morpholino, or $-N$  $N-R_{10}$;

25

R_8 is H, C_{1-6} alkyl, or $-(CH_2)_m-A$, with m being 2,3 or 4;

R_9 is H, C_{1-4} alkyl, $-(CH_2)_n-$  $-(R_{11})_p$, n is 1, 2, 3 or 4, p is 1,2 or 3;

30 R_{10} is H, C_{1-8} alkyl, C_{1-6} alkenyl, C_{4-6} cycloalkyl, cyclohexylmethyl, hydroxyalkyl (C_{2-6}), dihydroxyalkyl (C_{3-6}), C_{2-9} acyloxyalkyl (C_{2-6}), C_{1-4} alkoxyalkyl (C_{1-6}), $-(CH_2)_{2-6}-O-(CH_2)_{2-4}-OH$, $-(CH_2)_t-$  $-R_{12}$, with t

35

- 44 -

being 0, 1, or 2, or pyrimidinyl;
R₁₁ is H, C₁₋₄ alkoxy, C₁₋₄ alkyl or halogeno;
R₁₂ is ortho C₁₋₄ alkoxy, ortho C₁₋₄ alkyl or p-halo;aryl or
Q is a halogen⁰ or $\text{^0SO}_3\text{R}_1$ with R₁ being H, C₁₋₆ alkyl,
5 aralkyl.

2. The compound of Claim 1 wherein each R₂ are methyl.
3. The compound of Claim 1 wherein R₄ is methyl.
10
4. The compound of Claim 1 wherein R₅ is hydrogen.
5. The compound of Claim 1 wherein R₆ is methyl.
6. The compound of Claim 1 wherein A is $-\text{N}(\text{C}_6\text{H}_4)\text{N}-\text{R}_{10}$
15
7. The compound of Claim 6 wherein R₁₀ is methyl.
8. The compound of Claim 1 wherein the compound is
20 2,3-Dihydro-5-hydroxy-2,2,4,6,7-pentamethyl-1-benzofuran-3-carboxylic acid;
2,3-Dihydro-5-hydroxy-2,2,4,6,7-pentamethyl-1-benzofuran-3-methanol;
- 25 3-Bromomethyl-2,3-dihydro-2,2,4,6,7-pentamethyl-1-benzofuran-5-ol and O-acetate;
- 2,3-Dihydro-2,2,4,6,7-pentamethyl-3-dimethylaminomethyl-1-benzofuran-5-ol, hydrochloride;
- 30 2,3-Dihydro-5-hydroxy-N,N,N-2,2,4,6,7-octamethyl-1-benzofuran-3-methanaminium 4-methylbenzenesulfonate;
- 2,3-Dihydro-2,2,4,6,7-pentamethyl-3-(1-methylethylamino)-methyl-1-benzofuran-5-ol hydrochloride;
- 2,3-Dihydro-2,2,4,6,7-pentamethyl-3-(1-piperidino)methyl-1-benzofuran-5-ol;

- 45 -

- 2,3-Dihydro-2,2,4,6,7-pentamethyl-3-(4-methylpiperazino)-methyl-1-benzofuran-5-ol dihydrochloride;
- 5-Acetoxy-2,3-dihydro-2,2,4,6,7-pentamethyl-3-(4-methylpiperazino)methyl-1-benzofuran diacid maleate;
- 5 2,3-Dihydro-3-[4-(2-hydroxyethyl)piperazino]methyl-2,2,4,6,7-pentamethyl-1-benzofuran-5-ol diacid maleate;
- 5-Acetoxy-3-[4-(2-acetoxyethyl)piperazino]methyl-2,3-dihydro-2,2,4,6,7-pentamethyl-1-benzofuran diacid maleate;
- 10 2,3-Dihydro-3-[4-[2-(2-hydroxyethoxy)ethyl]piperazino]-methyl-2,2,4,6,7-pentamethyl-1-benzofuran-5-ol diacid maleate;
- 2,3-Dihydro-2,2,4,6,7-pentamethyl-3-[4-(2-pyrimidinyl)-piperazino]methyl-1-benzofuran-5-ol acid maleate;
- 15 2,3-Dihydro-2,2,4,6,7-pentamethyl-3-[4-(phenylmethyl)-piperazino]methyl-1-benzofuran-5-ol diacid maleate;
- 2,3-Dihydro-2,2,4,6,7-pentamethyl-3-[[2-(3,4-dimethoxy-phenyl)ethyl]methylamino]methyl-1-benzofuran-5-ol acid maleate;
- 20 3-Aminomethyl-2,3-dihydro-2,2,4,6,7-pentamethyl-1-benzofuran-5-ol hydrochloride;
- 3R and 3S-enantiomers of 5-Acetoxy-2,3-dihydro-2,2,4,6,7-pentamethyl-1-benzofuran-3-carboxylic acid;
- 3R-(+)- and 3S-(-)-enantiomers of 2,3-Dihydro-2,2,4,6,7-pentamethyl-3-(4-methylpiperazino)-methyl-1-benzofuran-5-ol
- 25 dihydrochloride hydrate;
- 2,3-Dihydro-5-hydroxy-2,2,4,6,7-pentamethyl-1-benzofuran-3-carboxylic acid ester with 1-(2-hydroxyethyl)-4-methyl-piperazine diacid maleate;
- 2,3-Dihydro-2,2,4,6,7-pentamethyl-3-(4-methylpiperazine-1-
- 30 carboxy)-1-benzofuran-5-ol acid maleate; or
- 2,3-Dihydro-2,2,4,6,7-pentamethyl-3-[4-(2-hydroxyethyl)-piperazine-1-carboxy]-1-benzofuran-5-ol acid maleate.

- 46 -

10. A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

11. A method of treating a patient for reperfusion
5 damage by administering an effective amount of a compound
of Claim 1.

12. A method of treating a patient for stroke or
nervous system trauma by administering an effective amount
10 of a compound of Claim 1.

13. A compound according to Claim 1 for use as a
pharmaceutically active compound.


15 14. A compound according to Claim 1 for use in the
treatment of stroke, nervous system trauma or reperfusion
damage.

20 15. A pharmaceutical composition according to Claim 14
for the treatment of stroke, nervous system trauma or
reperfusion damage.

25 16. Use of a compound according to Claim 1, optionally
in combination with a pharmaceutically acceptable carrier,
for the preparation of a pharmaceutical composition for the
treatment of stroke, nervous system trauma or reperfusion
damage.

17. The process of making a compound of the formula

5



(1)

10

the stereoisomers and mixtures thereof, and their pharmaceutically acceptable salts thereof, wherein

R_2 is C_{1-4} alkyl or both R_2 moieties, when taken together with the carbon atom to which they are attached, form a C_{5-6} cyclic hydrocarbyl moiety;

R_4 is C_{1-6} alkyl;

R_5 is H or $-C(O)R$ with R being H, or C_{1-9} alkyl;

R_6 is C_{1-6} alkyl;

R_7 is H or C_{1-6} alkyl;

X is $COOR_8$, CH_2OH , halomethyl, $C(O)A$ or $-CH_2A$;

A is $-NR_7R_9$, $-N^+R_6R_6R_6-Q^-$, pyrrolidino, piperidino

morpholino, or $-N$ $N-R_{10}$;

R_8 is H, C_{1-6} alkyl, or $-(CH_2)_m-A$, with m being 2,3 or 4;

R_9 is H, C_{1-4} alkyl, $-(CH_2)_n-$ $-(R_{11})_p$, n is

1, 2, 3 or 4, p is 1,2 or 3;

R_{10} is H, C_{1-8} alkyl, C_{1-6} alkenyl, C_{4-6} cycloalkyl,

cyclohexylmethyl, hydroxyalkyl (C_{2-6}), dihydroxyalkyl (C_{3-6}), C_{2-9} acyloxyalkyl (C_{2-6}), C_{1-4} alkoxyalkyl (C_{1-6}),

$-(CH_2)_{2-6}-O-(CH_2)_{2-4} OH$, $-(CH_2)_t-$ $-R_{12}$, with t


being 0, 1, or 2, or pyrimidinyl;

35

- 48 -

R_{11} is H, C_{1-4} alkoxy, C_{1-4} alkyl or halogeno;
 R_{12} is ortho C_{1-4} alkoxy, ortho C_{1-4} alkyl or p-halo;
 Ω is a halogen Θ or ΘSO_3R_1 with R_1 being H, C_{1-6} alkyl,
 aryl or aralkyl;


5 by reacting the compound



(5')

wherein Pg is C_{1-9} alkyl, $C(O)C_{1-9}$ alkyl, aryl or $C(O)$ aryl
 with thallium(III)(NO₃)₃ 3 H₂O in (CH₃)O₃CH and CH₃OH to
 produce


15



(6')

which is optionally hydrolyzed to produce

25




(7')

30

35


- 49 -

which is optionally reduced to produce




(8')

which is optionally halogenated to produce




(9')

15 or compound (8') is optionally aminated to produce



(10')

or compound (7') is optionally chlorinated to produce the acid chloride




(14')

30

35


- 50 -

and optionally reacted with Alcohol $\text{HO}(\text{CH}_2)_m\text{-A}$ to produce the ester



which can be optionally hydrolyzed to produce the phenolic alcohol,

- 10 or the acid chloride (14') can be optionally aminated to produce the amide



which can optionally be hydrolyzed to produce the phenolic acid.

20

25

30

35

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 93/02107

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶			
According to International Patent Classification (IPC) as to both National Classification and IPC			
Int.Cl. 5	C07D307/80; C07D405/06;	C07D307/79; C07D405/12;	C07D307/81; A61K31/34
II. FIELDS SEARCHED			
Minimum Documentation Searched ⁷			
Classification System		Classification Symbols	
Int.Cl. 5	C07D ;	A61K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸			
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹			
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²		Relevant to Claim No. ¹³
A	EP,A,0 413 668 (BIOMEDICA FOSCAMA INDUSTRIA CHIMICO-FARMACEUTICA S.P.A.) 20 February 1991 see page 2, line 1 - page 6, line 55; claims 1,19 ---		1
A	FR,A,2 634 766 (BIOMEDICA FOSCAMA INDUSTRIA CHIMICO-FARMACEUTICA S.P.A.) 2 February 1990 see page 1, line 1 - page 4, line 24; claim 1 ---		1
A	EP,A,0 281 261 (H. LUNDBECK A/S) 7 September 1988 see page 2, line 1 - line 54; claim 1; examples 13-23 ---		1
			-/-
<p>¹⁰ Special categories of cited documents:¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>¹¹ "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>¹² "Q" document member of the same patent family</p>			
IV. CERTIFICATION			
1 Date of the Actual Completion of the International Search 21 JUNE 1993		Date of Mailing of this International Search Report 30.06.93	
International Searching Authority EUROPEAN PATENT OFFICE		Signature of Authorized Officer CHOULY J.	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	<p>EP,A,0 345 593 (TAKEDA CHEMICAL INDUSTRIES, LTD.) 13 December 1989 see abstract and claims ----</p>	1
A	<p>US,A,4 975 457 (K.M. RUPPRECHT ET AL.) 4 December 1990 see abstract and claims ----</p>	1
T	<p>EP,A,0 483 772 (TAKEDA CHEMICAL INDUSTRIES, LTD.) 6 May 1992 see abstract; page 7, line 1-line 29 and claims 1,22 -----</p>	1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/02107

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 11 and 12 are directed to a method of treatment of (diagnostic method practised on) the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9302107
SA 71645

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

21/06/93

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0413668	20-02-91	AU-B-	634570	25-02-93
		AU-A-	6128090	21-02-91
		CA-A-	2023522	19-02-91
		CN-A-	1049499	27-02-91
		JP-A-	3236383	22-10-91
		US-A-	5114966	19-05-92
FR-A-2634766	02-02-90	BE-A-	1003255	11-02-92
		CH-A-	679583	13-03-92
		DE-A,C	3925496	22-02-90
		GB-A,B	2221463	07-02-90
		JP-A-	2078675	19-03-90
		SE-A-	8902603	02-02-90
		US-A-	4999350	12-03-91
		US-A-	5041568	20-08-91
EP-A-0281261	07-09-88	AU-B-	608293	28-03-91
		AU-A-	1216788	01-09-88
		DE-A-	3870666	11-06-92
		JP-A-	63264557	01-11-88
		US-A-	4847254	11-07-89
		US-A-	4946863	07-08-90
EP-A-0345593	13-12-89	JP-A-	2076869	16-03-90
		US-A-	4978761	18-12-90
US-A-4975457	04-12-90	CA-A-	2025478	26-03-91
		EP-A-	0420570	03-04-91
		JP-A-	3130277	04-06-91
EP-A-0483772	06-05-92	None		

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.